Drug Profile
Research programme: therapeutic cancer vaccines - Eterna Therapeutics
Alternative Names: IRX 4; IRX 5; IRX 6Latest Information Update: 17 Oct 2022
Price :
$50
*
At a glance
- Originator IRX Therapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Oct 2022 Brooklyn ImmunoTherapeutics is now called Eterna Therapeutics
- 07 Nov 2018 IRX Therapeutics has been acquired and merged into Brooklyn ImmunoTherapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA